Viagra Ingredient Shows Promise for Treating Leigh Syndrome

Sildenafil – the active ingredient in Viagra – is demonstrating positive effects in patients with Leigh syndrome, a rare and devastating childhood metabolic disorder. Recent research, published in the journal Cell, indicates the drug may improve symptoms and quality of life for those affected by this currently incurable condition.

Understanding Leigh Syndrome

Leigh syndrome is a genetic disorder that affects the brain and muscles, stemming from a defect in energy metabolism. Typically manifesting in infancy or early childhood, the syndrome causes progressive neurological damage, leading to symptoms such as seizures, muscle weakness, and developmental delays. The prognosis for children with Leigh syndrome is often poor, with many succumbing to the disease within a few years of diagnosis. It affects approximately one in 36,000 live births, classifying it as a rare disease .

The Unexpected Discovery: Sildenafil’s Role

Researchers initially identified sildenafil as a potential treatment through a large-scale drug screening process. An international team tested over 5,500 existing drugs on nerve cells cultured from the skin cells of Leigh syndrome patients . Sildenafil emerged as a promising candidate, improving the electrical functionality of the nerve cells in laboratory settings. Further testing in three-dimensional brain models (organoids) showed that sildenafil enhanced nerve cell growth and improved energy metabolism .

Pilot Study Results

A pilot study involving six patients aged between 9 months and 38 years showed encouraging results. Patients receiving sildenafil experienced improvements in muscular strength, and some saw a reduction or elimination of neurological symptoms. Notably, patients also demonstrated faster recovery from metabolic crises – sudden worsening of the condition due to energy metabolism overload . For example, one child increased their walking distance tenfold, from 500 to 5,000 meters . Other patients experienced a suppression of monthly metabolic crises and a cessation of epileptic seizures .

Clinical Trials and Orphan Drug Designation

Following the positive results from the initial study, the European Medicines Agency (EMA) has granted sildenafil orphan drug designation for the treatment of Leigh syndrome . This designation facilitates a streamlined approval process for drugs targeting rare diseases. Researchers are now planning a Europe-wide, placebo-controlled clinical trial, as part of the SIMPATHIC EU project, to further validate these findings and pave the way for potential approval of sildenafil as a treatment for Leigh syndrome . The first patient was treated at Charité – Universitätsmedizin Berlin, with subsequent patients treated in Düsseldorf, Munich, and Bologna .

Safety and Future Outlook

The initial studies indicate that sildenafil is well-tolerated by patients with Leigh syndrome. The drug’s safety profile is further supported by its existing approval for other pediatric conditions, providing detailed long-term safety data . While further research is needed, the discovery of sildenafil as a potential treatment offers a significant glimmer of hope for individuals and families affected by this devastating disease .